Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers

Launched by TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER · Mar 28, 2023

Keywords

ClinConnect Summary

The LOGIC clinical trial is studying a new treatment approach for women with triple negative breast cancer, which is a more aggressive form of the disease. This trial aims to combine two methods: cryoablation, a procedure that freezes and destroys cancer cells while preserving important tumor proteins, and checkpoint inhibitors, which help the immune system recognize and destroy cancer cells. The researchers believe that using these two methods together could improve the chances of a better response to treatment and overall survival for patients.

To participate in this trial, women aged 18 to 90 with stage I or II triple negative breast cancer may be eligible. Key criteria include having a specific type of cancer that is not influenced by hormone levels and having a single tumor that can be seen on an ultrasound. Participants can expect to receive close monitoring and care throughout the trial, which is not yet recruiting. It's important to note that individuals with certain health conditions or treatments, like autoimmune diseases or recent vaccinations, may not qualify for this study.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Females
• • Stage I/II Cancer
• • Age range 18 - 90 years
• • Diagnoses: Invasive carcinoma, ER -, PR-, HER2- (triple negative)
• • Radiology findings: Unifocal disease visible on ultrasound
• Exclusion Criteria:
• • Additional primary cancer
• • Inflammatory breast cancer
• • History of autoimmune disease
• • History of chronic immunosuppression
• • Prior immunotherapy
• • Recent vaccination (within 4 wks.)
• • Prior radiation therapy
• • Prior investigational agent therapy within last 1 year
• • Pregnancy at the time of diagnosis and/ or treatment
• • Breast feeding